Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
YOU see MVIS today? IT has an r/s then got upgraded lol ran 2.30 to 3.43
Thanks..
lol saw it..and thought idiot to not buy
ADNT i show .23x.30
THLD what a beauty today had news..4.40 yesterday hit 6.19 wow
GALE 1.26 sinking..only good for pops in morning now it seems
JSDA..lol we like it if it goes up always
did u make out?
Screaming..lol I just realized...rofffffffffff snort
??????????? i dont have beard!!! lol
Good lol
CBLI at support 3.28 ran hard last time
FFN hit highs 1.63
Stay away if your not in and out now..ran too fast
VRS hit 3.10 160%
FFN hit 1.55
VRSSSSSSSSSSSS hit 2.40!!!!!!!!!!!!!
VRS 2.20 monster news from yesterday
MNI ........hit 2.90
HIT 2.18 market liked yesterdays news
VRS was at support in their too..paper one
Have all newspapers in a list..just saying..lol
FFN back to some support too at 1.30
MNI i knew it..lol saw yesterday at support at 2.55 now 2.82
MOTR been popping again
seems toppy
weeeeee1.94!
VRS was 1.44 when i saw it hit 1.80
VRS man ..
IT has been giving nice bounces every day
who knows..down alot from highs but they also have 10m s8 i think
gm yah it is..I can find nothing for safe entry and exciting lol
CLDX GNOM humm
XOMA news (Track Notes) XOMA Jumps on Positive Diabetes Treatment Study; Shares Add 8.1%
XOMA Jumps on Positive Diabetes Treatment Study; Shares Add 8.1%
09:07 AM EST, 03/08/2012 (MidnightTrader) -- XOMA (XOMA) is up 8.1% at $2.00 a
share before the bell after results of a study into XMetA, the company's
fully-human allosteric monoclonal antibody to the insulin receptor,
demonstrate that it has the potential to be a novel, long-acting agent for the
control of blood glucose levels in patients with diabetes.
IPSU the sugar one..wow what a gap
Well Hello for CA! glad you made it safely..you must be exhusted.
wow
ALXA had news ah last night,,but it is also diluted 22m previous share offering..so becareful (COMTEX) B: Alexza and Grupo Ferrer Amend Adasuve(TM) Partnership ( PR New
B: Alexza and Grupo Ferrer Amend Adasuve(TM) Partnership ( PR Newswire )
MOUNTAIN VIEW, Calif. and BARCELONA, Spain, March 7, 2012 /PRNewswire via
COMTEX/ --
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional,
S.A. (Ferrer), announced today that they have amended their commercial
partnership agreement for Adasuve(TM) (Staccato® loxapine). In October 2011,
Alexza and Ferrer established a partnership for the commercialization of
ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent
States countries. With this amendment, Ferrer will expand its strategic
partnership by becoming an Alexza stockholder. Ferrer and Alexza have agreed
to eliminate a future potential milestone payment in exchange for the
purchase of Alexza common stock. Ferrer will purchase approximately 2.42
million shares of Alexza common stock for $1.24 per share. During 2012, up
to an additional $8 million of Alexza common stock may be purchased by
Ferrer, upon a request by Alexza and subject to acceptance by Ferrer, in
exchange for the elimination of additional milestones at a price per share
that will be a premium to the market price on the date of purchase.
Alexza and Ferrer also announced Ferrer's intent to submit product
registrations for ADASUVE in Brazil and Mexico. These two Latin American
registrations submissions represent Ferrer's first two non-European Union
ADASUVE regulatory filings.
"We welcome the opportunity to expand our partnership with Alexza," said
Antoni Villaro, Chief Operating Officer of Grupo Ferrer. "ADASUVE fits
perfectly into our specialty pharmaceutical portfolio. If approved for
marketing, we believe that the unique therapeutic benefits ADASUVE provides
will capture physicians' and patients' interest, and establish it as an
important new tool in the treatment of agitation."
"We are very pleased with the strengthening of our strategic partnership and
alliance with Grupo Ferrer," said Thomas B. King, Alexza's President and CEO.
"In the first four months of our partnership, teams from both companies have
worked to expand the integration of the ADASUVE work, strategies and
responsibilities. We share great passion for the product and a strong sense
of camaraderie toward building long-term success."
King continued, "We are also excited to support Ferrer's upcoming
submissions of the ADASUVE registrations for Brazil and Mexico. We feel
these filings demonstrate Ferrer's commitment to ADASUVE as they work to
bring this important product to patients."
About ADASUVE (Staccato loxapine)ADASUVE is an anti-agitation therapeutic
that combines Alexza's proprietary Staccato system with loxapine, an
antipsychotic drug. Loxapine is currently available in oral and other
formulations, inside and outside of the U.S. and European Union. The
Staccato system is a hand-held, single-dose inhaler that delivers a drug
aerosol to the deep lung that results in IV-like pharmacokinetics and rapid
systemic effects. Click here to see an animation of how the Staccato system
works.
As an easy-to-use, non-coercive and highly reliable inhaled therapeutic that
DRRX .87
showoff.....lol
HDY still tries to go over highs